Psychosocial Aspects of Multiple Endocrine Neoplasia (MEN) Syndromes

Official Title: “Psychosocial Aspects of Multiple Endocrine Neoplasia (MEN) Syndromes”

The specific aims of the study include:

1. Profile the demographic, health-related, psychosocial and behavioral characteristics of adults with MEN1 or MEN2.

2. Evaluate MEN-specific distress as well as adherence to surveillance regimens among adults with MEN1 or MEN2, and identify associated with those outcomes.

The proposed cross-sectional study is intended to obtain information regarding current surveillance behaviors and other psychosocial outcomes among persons affected by the multiple endocrine neoplasia (MEN) 1 or MEN2, which are inherited conditions.

Study participants will include patients who have been seen previously at MDACC for evaluation of MEN1 or MEN2. Because this is the first time investigators are contacting these patients to invite them to participate in psychosocial research, the proposed study also will help determine the feasibility of conducting similar studies in the future.

Investigators anticipate that data gathered from this study will enhance existing knowledge about the psychological and behavioral aspects of the MEN syndromes, and will inform future research efforts directed toward this understudied population.

Intervention(s) in this Clinical Trial

• Behavioral: Questionnaire
  • Mailed packets including cover letter describing purpose of study, study questionnaire, and return envelope.

Arms, Groups and Cohorts in this Clinical Trial

• : MEN
  • Patients with multiple endocrine neoplasia (MEN).

Primary Measures

• Profile the demographic, health-related, psychosocial and behavioral characteristics of adults with MEN1 or MEN2.
  • Time Frame: 3 Years
    Safety Issue?: No

Inclusion Criteria:

• 1. Adults age 18 years or older, with a clinical or genetic diagnosis of MEN1 or MEN2
• 2. Spouse, Significant Other, or Family Member who is at least 18 years of age and who is related to an individual who is a patient at MDACC and who has been diagnosed with MEN1.
• 3. Ability to read and write English

Exclusion Criteria:

• 1) Inability to be contacted via mail (i.e., no contact information on record, incorrect address)

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Investigator: M.D. Anderson Cancer Center Other

Overall Clinical Trial Officials and Contacts

Susan Peterson, PhD Principal Investigator M.D. Anderson Cancer Center  

Overall Contact: Susan Peterson, PhD 713-792-8267 

Information obtained from ClinicalTrials.gov on February 12, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00501449

Study ID Number: 2006-0783

ClinicalTrials.gov Identifier: NCT00501449

Health Authority: United States: Institutional Review Board

MD Anderson Cancer Center